89bio was acquired by Roche in September 2025, making the company a member of the Roche Group. We look forward to advancing our innovative FGF21 analog, pegozafermin, as part of Roche’s Pharmaceuticals Division and continuing our mission to help patients with serious liver and cardiometabolic diseases. Pegozafermin is currently being evaluated in Phase 3 trials for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG).
Looking for a particular 89bio employee's phone or email?
89bio Questions
The 89bio annual revenue was $14.8 million in 2026.
Francis Sarena is the COO of 89bio.
111 people are employed at 89bio.
89bio is based in San Francisco, California.
The NAICS codes for 89bio are [54, 32, 325, 541, 32541, 3254].
The SIC codes for 89bio are [283, 873, 28, 87].
Top 89bio Employees
-
Francis Sarena
Chief Operating Officer at 89bio
San Francisco, CA, US45+ -
Rohan Palekar
CEO at 89bio
California, United States21 -
Ryan Martins
Chief Financial Officer at 89bio
San Mateo, CA, US35+ -
Hank Mansbach
Chief Medical Officer at 89bio
San Francisco, CA, US21 -
Annie CHANG
Vice President, Investor Relations and Corporate Communications at 89bio
San Francisco, CA, US22 -
Shiva Natarajan
SVP Finance and Principal Accounting Officer at 89bio
California, United States35+ -
Anna Sedello
Vice President Regulatory Affairs at 89bio
California, United States24 -
Wenyan Wang
Vice President Clinical Develpment at 89bio
Montgomery, NJ, US1 -
Shaji Joseph
Vice President CMC at 89bio
California, United States24
Related Companies
